Layer 03 · Decision Layer

Executive / dashboard

CFO · COO view · read-only

Nine numbers. Read once each morning. Three of them are your weekly board narrative.

Today's Executive Brief

Q4 forecast +6.2% vs plan; AR at risk = $60.4K.

ONCO-241 is the top revenue contributor for Q4 (forecast $539.6K).
Three invoices crossed the 60-day AR bucket — recommend collections sweep.
Pipeline coverage at 27% — Oncology + Endo gaps are the easiest to close first.
Enrollment revenue leakage = $331.2K — sub-I → PI handoff is the largest single bucket.

Projected 90-day rev

$1.61M

+6.2% vs plan

12-month revenue

$4.87M

FY model

Invoice-ready revenue

$318.4K

82 events

AR at risk

$60.4K

10 invoices · 60+ d

Enrollment revenue gap

$331.2K

across 5 leakage points

Studies closing soon

next 60 days

Contracting gap

358

uncontracted opportunities

Pipeline coverage

27%

of TA-relevant trials

Board pack · ready

Q3 2025 — auto-assembled from these 9 metrics

Export PDF / PPTX

Cash Position · demo data bank feed · not connected

Cash Balance

$1.28M

as of 2/18/2026

Expected Inbound AR

$612K

recoverable · 90-day window

Runway Estimate

7.2 mo

at $178K / mo burn

Bank Feed Status

Not Connected

Plaid integration · coming later

Projected balance · cash forecast

30-day forecast

$1.43M

$412K $269K

60-day forecast

$1.59M

$529K $366K

90-day forecast

$1.76M

$643K $471K

Revenue Forecast · 6 quarters

Open Finance →

Top TA Opportunities

Open Watcher →

Oncology
142 open · fit avg 84
$2.84M
expected
Endocrinology
88 open · fit avg 79
$1.62M
expected
Cardiology
96 open · fit avg 76
$1.41M
expected
Immunology
71 open · fit avg 71
$980.0K
expected

Studies Closing Soon · next 60 days

Study	Indication	Closes	Remaining Rev
ONCO-241	NSCLC III	2025-12-04	$539.6K	drill →
DERM-302	Atopic Derm	2025-12-18	$319.2K	drill →
GI-211	Crohn's	2026-01-08	$275.2K	drill →
ENDO-156	T2D	2026-01-22	$321.3K	drill →

Live Alerts

4 active

ONCO-241 enrollment 6 patients behind plan — sub-I capacity flagged.
12m ago
3 invoices crossed 60-day AR bucket — $42.8K at risk.
1h ago
PF-2255 advanced to Phase III in Immunology — fit score 84.
3h ago
CARDIO-118 screening conversion dropped to 58% (−9pt WoW).
5h ago

Recruitment Engine

PI / Sub-I performance · enrollment leakage · comp run

Open

Finance Command

Upload · forecast · invoice readiness · AR

Open

Pharma Watcher

Contracting gap · pipeline · TA heatmap

Open